All In Biotech

Drug Trial Radar · NCT07246564

Phase 4 Study Evaluating Efficacy and Safety of Rozanolixizumab in Adult Chinese Participants With Generalized Myasthenia Gravis

An Open-label, Prospective, Single-arm Study Assessing the Efficacy and Safety of Rozanolixizumab in Adult Chinese Participants With Generalized Myasthenia Gravis

Last checked: Nov 20, 2026Latest source record: Nov 20, 2026 (this record)Source: ClinicalTrials.govMethods & limitations

Active, not recruiting

Status

Active, not recruiting

Enrollment

40

Actual

Start

Dec 1, 2025

Primary completion

Jun 3, 2027

Study completion Jun 3, 2027

Sponsor

Lead sponsor
UCB Biopharma SRLUCB
Sponsor type
Industry
First posted
Nov 24, 2025

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 4
Allocation
Not applicable (single group)
Model
Single group
Masking
None
Primary purpose
Treatment
FDA-regulated drug
No
Who can join
All sexes, from 18 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

The purpose of the study is to assess the clinical efficacy of rozanolixizumab in adult Chinese participants with generalized myasthenia gravis (gMG) in the first Treatment Cycle.

Conditions

  • Myasthenia Gravis

Interventions

  • RozanolixizumabDrug

    Subcutaneous infusion

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Change from Baseline to Day 43 in Myasthenia Gravis-Activities of Daily Living (MG-ADL) score in the first Treatment CycleTime frame: Baseline to Day 43 (in first treatment cycle)

Locations

12 sites in 1 country. Site status is shown where the registry gives one.

  • Mg0033 20040

    Beijing, China

  • Mg0033 20261

    Changchun, China

  • Mg0033 20295

    Changsha, China

  • Mg0033 20348

    Fuzhou, China

  • Mg0033 20269

    Guangzhou, China

  • Mg0033 20185

    Jinan, China

  • Mg0033 20347

    Jinan, China

  • Mg0033 20172

    Shanghai, China

  • Mg0033 20184

    Shenzhen, China

  • Mg0033 20204

    Suzhou, China

  • Mg0033 20180

    Wuhan, China

  • Mg0033 20349

    Xuzhou SHI, China

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.